March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
Daridorexant can't reach the heights of its first pivotal study win, but a pooled analysis could still save it.
Daridorexant scores in the first of two phase III insomnia studies, but attention will fall on a secondary endpoint measuring daytime performance.
Novartis’s similarly acting fevipiprant had failed in asthma in October, and today it fails in the more important severe setting.
The cystic fibrosis player does deals with Crispr and Exonics to launch itself into a highly competitive rare disease area.
The Bristol-Myers Squibb and Amicus drugs face approval decisions next week.